Pharma R&D Today

Reaxys User Day 2022: Sharing insights and tips for streamlining the chemist workflow

Posted on June 14th, 2022 by Louise Springthorpe

Whether you are an academic seeking a potential next-level cancer treatment, a pharma company charting out the competitive landscape, or a researcher wanting to stay on top of the latest bioactivity and pharmacological data relevant to your specialty, the Reaxys User Day 2022 proved a cornucopia of tips and tricks for chemists on how to streamline their workflow. Now, in case you missed the big day, these presentations are now online. Watch and learn.

Busy healthcare professionals can rely on phactMI

Posted on June 9th, 2022 by Louise Springthorpe

When patients go to see a doctor, nurse or some other kind of healthcare professional (HCP), they are expecting to benefit from that person’s experience and education in their field. HCPs accrue a great deal of knowledge over time, but of course they can’t know everything. An important part of being an effective healthcare provider is knowing where to look.

But often HCPs hit a roadblock when seeking good, reliable information on pharmaceutical drugs.

How pharma can make drug information accessible

Posted on June 1st, 2022 by Louise Springthorpe

Pharmaceutical drugs can work wonders for patients, whether it’s treating rare diseases or easing everyday maladies. But drugs can also be complex. What works for one patient may not for another, and side effects could be possible. Also, the longer that a drug is on the market, the more its manufacturer might learn and document about its effects. All of this information is important, and in order to prescribe drugs wisely, doctors need access to it.

Reaxys User Day 2022: Researcher secrets in the spotlight

Posted on May 26th, 2022 by Louise Springthorpe

In April, Elsevier hosted the first Reaxys User Day to learn from expert users and share best practices. Attendees were also updated on how the expert-curated chemistry database has dramatically upped its ability to streamline R&D. We spoke with senior director Ivan Krstic about how Reaxys is turning data into actionable insights to better understand the competitive landscape, design novel compounds, and generally accelerate synthetic chemistry. “Today is about sharing the amazing strides we’ve made,” says Ivan.

Taking on the Net Zero challenge at the government level

Posted on May 24th, 2022 by Ann-Marie Roche

Life sciences companies are increasingly committing themselves to Net Zero goals, laying out plans for reaching zero emissions by 2050 or earlier. This is a vitally important step for industry. But national, state and city governments also have a critical role in reducing emissions created by various sectors under their jurisdiction.

Pharma’s path to Net Zero

Posted on May 3rd, 2022 by Ann-Marie Roche

Pharma is seldom top of mind when thinking about the most polluting industries, but pharmaceutical industry operations are in fact responsible for a significant portion of the world’s greenhouse gas emissions – even rivaling industries that are far more associated with contributing to the problem. 

About this Blog

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.